Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00245700
NCT00245700CompletedNot Applicable

Study of Adherence of Stalevo, Entacapone and Levodopa

South Glasgow University Hospitals NHS Trust1 site in 1 country14 target enrollmentStarted: April 2005Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
14
Locations
1
Study OverviewEligibility CriteriaInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

To test if combining two antiparkinson drugs into a single tablet improves accuracy of medicine intake by the patient.

To test if patients with Parkinson's disease who take medicines at regular time intervals have smoother symptom control.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients diagnosed with Parkinson's disease aged between 18 and 85 years fulfilling UK Brain Bank criteria.
  • •Current levodopa therapy prescribed on a regular basis three or more times per day but requiring entacapone because of 'wearing off'
  • •Able to manipulate electronic monitoring bottles and complete questionnaires

Exclusion Criteria

  • •Current use of compliance aid such that study participation would be detrimental to patient's adherence
  • •Pregnancy or breast feeding
  • •Excess alcohol (over 21 units per week for women and 28 units for men)
  • •Mini mental state examination of less than
  • •Severe depression (Geriatric depression score over 20)

Investigators

Sponsor
South Glasgow University Hospitals NHS Trust
Sponsor Class
Other

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 2
Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast CancerBreast Neoplasm
NCT00194727University of Washington40
Completed
Phase 2
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerBRAF V600E-mutant Metastatic Colorectal Cancer
NCT03693170Pierre Fabre Medicament95
Completed
Phase 2
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)Urethritis
NCT00322465National Institute of Allergy and Infectious Diseases (NIAID)305
Withdrawn
Phase 3
An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient InsomniaTransient Insomnia
NCT03338764Sequential Medicine Ltd
Completed
Phase 3
Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and VomitingChemotherapy-induced Nausea and Vomiting
NCT02484911First Affiliated Hospital of Harbin Medical University120